{
  "docId": "019de073-a711-71bb-a4fc-67d28d18b8d8",
  "docSlug": "26ea3d305f04fe3e604b448e70b259ea",
  "documentTitle": "BenevolentAI | Investor Presentation Deck | 46 slides",
  "authorId": "benevolentai",
  "authorName": "BenevolentAI",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 17,
  "pageCount": 46,
  "prevPage": 16,
  "nextPage": 18,
  "slideType": "traction",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 16,
  "notes": "The table presents financial data in thousands of pounds (£'000) for the six months ended June 30th.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-a711-71bb-a4fc-67d28d18b8d8/17",
  "deckHref": "/decks/019de073-a711-71bb-a4fc-67d28d18b8d8",
  "deckJsonHref": "/decks/019de073-a711-71bb-a4fc-67d28d18b8d8.json",
  "deckAnchorHref": "/decks/019de073-a711-71bb-a4fc-67d28d18b8d8#slide-17",
  "components": [
    {
      "bbox": {
        "h": 0.05,
        "w": 0.7,
        "x": 0.05,
        "y": 0.88
      },
      "kind": "disclaimer",
      "text": "1) Excludes exceptional costs related to the Business Combination 2) Normalised EPS also excludes taxation impact from exceptional items and finance income related to the Business Combination",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3c762212-0284-4789-a521-400dc24241cc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.28,
        "x": 0.68,
        "y": 0.2
      },
      "kind": "list",
      "text": "Revenue increase across AstraZeneca collaboration. DD spend increase driven by portfolio advancing. P&T spend increase reflecting increased headcount. Bus Ops spend +15%, driven by listing status.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a154ab6b-5fae-4cf8-bd40-cc1b11d085e9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.6,
        "x": 0.05,
        "y": 0.22
      },
      "kind": "table",
      "text": "Revenue, R&D - Drug discovery, R&D - Product & technology, G&A - Business operations, Underlying expenses, Other income, Normalised operating loss, Normalised EPS, Weighted average ordinary shares outstanding",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8823f919-42d9-4bfd-883f-6e66de5a16bc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.4,
        "x": 0.05,
        "y": 0.06
      },
      "kind": "title",
      "text": "1H 2022 Financial highlights",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3bf4f762-e3d8-49ee-94f3-3807c271d68e",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "18f8c60c-a7f4-411c-8c6e-eef767ccf66b",
      "evidence": "table/data: Revenue, R&D - Drug discovery, R&D - Product & technology, G&A - Business operations, Underlying expenses, Other income, Normalised operating loss, Normalised EPS, Weighted average ordinary shares outstanding",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 18,
      "from": 17,
      "beatId": "9fdd1295-746e-42e7-9135-928557413ad2",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Financials",
      "beatSlug": "sequoia-pitch-financials",
      "evidence": "1H 2022 Financial highlights and cash runway",
      "position": 4,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}